Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.45 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3616559 | 1.00 | OPRM1 (0.50) | OPRM1OPRD1OPRK1LTA4HMAP3K7 | |
| SCHEMBL3179345 | 0.88 | SRD5A2 (0.56) | OPRM1OPRD1OPRK1ALDH1A1L3MBTL1 | |
| SCHEMBL3179354 | 0.88 | SRD5A2 (0.56) | OPRM1OPRD1OPRK1ALDH1A1L3MBTL1 | |
| SCHEMBL8175136 | 0.81 | NPC1 (0.57) | ALDH1A1KDM4EMMP1MMP2NPC1 | |
| SCHEMBL9865069 | 0.80 | KMT2A (0.64) | ALDH1A1L3MBTL1NPC1RAB9ASRD5A2 | |
| SCHEMBL17339657 | 0.79 | NNMT (0.54) | ALDH1A1KDM4ENPC1RAB9AMEN1 | |
| SCHEMBL3607620 | 0.78 | KMT2A (0.52) | OPRM1ALDH1A1L3MBTL1KDM4ENPC1 | |
| SCHEMBL8164709 | 0.78 | KMT2A (0.52) | OPRM1ALDH1A1L3MBTL1KDM4ENPC1 | |
| SCHEMBL14350431 | 0.77 | KDM4E (0.50) | OPRM1OPRD1OPRK1LTA4HALDH1A1 | |
| SCHEMBL9836849 | 0.77 | TBXAS1 (0.53) | LTA4HALDH1A1L3MBTL1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304438-B2 | Heteroarylacrylamides and their use as pharmaceuticals | SANOFI (FR) | 2012-11-06 | — | — | US | disclosed |
| US-8304438-B2 | Heteroarylacrylamides and their use as pharmaceuticals | SANOFI (FR) | 2012-11-06 | — | — | US | disclosed |
| US-8304438-B2 | Heteroarylacrylamides and their use as pharmaceuticals | SANOFI (FR) | 2012-11-06 | — | — | US | disclosed |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2099753-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-09-16 | — | — | EP | disclosed |
| EP-1939180-A1 | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939180-A1 | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074413-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS FOR THE STIMULATION OF THE EXPRESSION OF ENDOTHELIAL NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | NOS3, PTGIS, NOS1 | OPRM1 235/4885OPRD1 1825/4885OPRK1 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.